|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Datamonitor, July 2008, Pages: 96
The antihypertensives market is expected to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartiss Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizers Norvasc and Mercks Cozaar, will restrain market growth.
Scope
- Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.
- Definition of the unmet needs in the antihypertensives market.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the hypertension market.
Highlights of this title
The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.
Cozaars and Diovans patent expiries in the US have the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve moderate sales and together with Exforge form a potential for market expansion. This however will be set back by the premature expiry of Pfizers Norvasc patent.
Key reasons to purchase this title
- Quantify the future size of the antihypertensives market and identify opportunities for new products.
- Learn how recent changes related to product expiries will shape the antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.
Customers who bought this item also bought
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
The World Market for Gynaecology, 2007-2017
Hypertension: Treatments and Prescribing Practices - A Global Survey
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Strategic Analysis of the Kenyan Hypertension Markets
China Hypertension Drug Market 2008
Antihypertensives - Two Years to Shape the Market?
Chinese Markets for Hypertension Drugs
Renin Inhibitors: A Novel Approach to Hypertension
Competitor Analysis: Antihypertensives
Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value?
|
|
|
|
